Caris Life Sciences (CAI) Liabilities and Shareholders Equity (2024 - 2026)

Caris Life Sciences' Liabilities and Shareholders Equity history runs 3 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity changed N/A year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $4.2 billion, a 1129.93% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 227.48% from the prior year.
• Liabilities and Shareholders Equity rose to $1.2 billion in Q1 2026 per CAI's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.2 billion in Q1 2026 and bottomed at $343.7 million in Q4 2024.
• The 3-year median for Liabilities and Shareholders Equity is $984.6 million (2025), against an average of $914.3 million.
• Biggest YoY gain for Liabilities and Shareholders Equity was 227.48% in 2025; the steepest drop was 227.48% in 2025.
• Year by year, Liabilities and Shareholders Equity stood at $343.7 million in 2024, then soared by 227.48% to $1.1 billion in 2025, then increased by 3.26% to $1.2 billion in 2026.
• Per Business Quant, the three latest CAI Liabilities and Shareholders Equity figures stand at $1.2 billion (Q1 2026), $1.1 billion (Q4 2025), and $984.6 million (Q3 2025).